180 related articles for article (PubMed ID: 30997192)
1. Hyperprogressive disease: a distinct effect of immunotherapy?
Popat V; Gerber DE
J Thorac Dis; 2019 Mar; 11(Suppl 3):S262-S265. PubMed ID: 30997192
[No Abstract] [Full Text] [Related]
2. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.
Sun D; Liu D; Liu Q; Hou H
Cancer Biol Ther; 2020 Dec; 21(12):1097-1104. PubMed ID: 33151119
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report.
Xu S; Shukuya T; Shimamura S; Hayashi T; Sato Y; Shiozaki H; Nishioki T; Nishino K; Kato M; Hattori A; Shimada N; Suzuki K; Kitano S; Takahashi K
Transl Lung Cancer Res; 2024 Mar; 13(3):666-672. PubMed ID: 38601437
[TBL] [Abstract][Full Text] [Related]
4. Is hyperprogressive disease a specific phenomenom of immunotherapy?
Brambilla M; Russo GL; Ferrara R; Manglaviti S; Garassino MC; Occhipinti M
Explor Target Antitumor Ther; 2020; 1(6):427-433. PubMed ID: 36046388
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer.
Li Y; Chen T; Nie TY; Han J; He Y; Tang X; Zhang L
Front Immunol; 2023; 14():1200875. PubMed ID: 37283759
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Camelliti S; Le Noci V; Bianchi F; Moscheni C; Arnaboldi F; Gagliano N; Balsari A; Garassino MC; Tagliabue E; Sfondrini L; Sommariva M
J Exp Clin Cancer Res; 2020 Nov; 39(1):236. PubMed ID: 33168050
[TBL] [Abstract][Full Text] [Related]
7. Histopathologic Evolution of Melanocytes Associated With Rapid Clinical Progression of Melanoma: Clinicopathologic Presentation of Hyperprogressive Disease in a Patient Treated With Immunotherapy.
Almanza J; Dobry A; Ejadi S; Jakowatz J; Lee B
Am J Dermatopathol; 2022 Dec; 44(12):921-924. PubMed ID: 36395449
[TBL] [Abstract][Full Text] [Related]
8. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors.
Toki MI; Syrigos N; Syrigos K
Int J Cancer; 2021 Jul; 149(2):277-286. PubMed ID: 33300601
[TBL] [Abstract][Full Text] [Related]
9. Hyperprogressive Disease: Main Features and Key Controversies.
Arasanz H; Zuazo M; Bocanegra A; Chocarro L; Blanco E; Martínez M; Morilla I; Fernández G; Teijeira L; Morente P; Echaide M; Castro N; Fernández L; Garnica M; Ramos P; Escors D; Kochan G; Vera R
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916696
[TBL] [Abstract][Full Text] [Related]
10. Hyperprogressive disease: recognizing a novel pattern to improve patient management.
Champiat S; Ferrara R; Massard C; Besse B; Marabelle A; Soria JC; Ferté C
Nat Rev Clin Oncol; 2018 Dec; 15(12):748-762. PubMed ID: 30361681
[TBL] [Abstract][Full Text] [Related]
11. [Advances in Hyperprogressive Disease in Patients
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
Yao S; Shi K; Zhang Y
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
[TBL] [Abstract][Full Text] [Related]
12. Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy.
Wei Z; Zhang Y
Cells; 2022 May; 11(11):. PubMed ID: 35681453
[TBL] [Abstract][Full Text] [Related]
13. [Immune checkpoint inhibitors-related hyperprogressive disease: a case report].
Zhang JY; Peng YM; Tan KX; Shen W; Zhang X; Sun CY; Cui HJ
Zhonghua Zhong Liu Za Zhi; 2021 Sep; 43(9):979-980. PubMed ID: 34530583
[No Abstract] [Full Text] [Related]
14. Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy.
Kurman JS; Murgu SD
J Thorac Dis; 2018 Feb; 10(2):1124-1128. PubMed ID: 29607190
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma.
Hu CH; Shi S; Dong W; Xiao L; Zang H; Wu F
Front Oncol; 2022; 12():799549. PubMed ID: 35321429
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report.
Dong S; Liu K; Liu R; Zhuang J
Exp Ther Med; 2022 Oct; 24(4):617. PubMed ID: 36160895
[TBL] [Abstract][Full Text] [Related]
17. Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy.
Gomes da Morais AL; de Miguel M; Cardenas JM; Calvo E
Cancer Treat Rev; 2020 Dec; 91():102116. PubMed ID: 33157360
[TBL] [Abstract][Full Text] [Related]
18. Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[
Nakamoto R; C Zaba L; Rosenberg J; Arani Reddy S; W Nobashi T; Ferri V; Davidzon G; Mari Aparici C; Nguyen J; Moradi F; Iagaru A; Lewis Franc B
Mol Imaging Biol; 2021 Feb; 23(1):139-147. PubMed ID: 32789649
[TBL] [Abstract][Full Text] [Related]
19. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
[TBL] [Abstract][Full Text] [Related]
20. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
